Table 1.
Demographic Details of Study Participants
| Variable | Control Subjects (n = 21) | Patients (n = 29) | p Value |
|---|---|---|---|
| Male | 13 (62) | 22 (76) | .45a |
| Age, Years | 23.3 ± 3.4 | 25.5 ± 4.2 | .06b |
| Ethnicity, White British | 14 (67) | 10 (35) | .05a |
| Current Smoker | 5 (24) | 12 (41) | .32a |
| Right-handed | 19 (90) | 26 (90) | .99a |
| Education, Years | 16.8 ± 1.9 | 14.2 ± 3.4 | .002b |
| Medication Status | |||
| Antipsychotic naïve | NA | 11 (38) | NA |
| Minimally treatedc | NA | 2 (7) | NA |
| Antipsychotic free | NA | 16 (5) | NA |
| Diagnosis | |||
| Schizophrenia | NA | 15 (52) | NA |
| Bipolar | NA | 12 (41) | NA |
| Other | NA | 2 (7) | NA |
| Days Between PET and MRI Scans | 70 (24–250; 4–733) | 8 (3–24; 1–371) | <.001d |
| PANSS Total | NA | 66.7 ± 20.7 | NA |
| PANSS Positive | NA | 17.6 ± 6.9 | NA |
| PANSS Negative | NA | 15.1 ± 6.3 | NA |
| PANSS General | NA | 34.0 ± 10.1 | NA |
| Injected Activity, MBq | 152.9± 12.6 | 143.5 ± 7.4 | .01b |
Data are expressed as n (%), mean ± SD, or median (interquartile range; range).
MRI, magnetic resonance imaging; NA, not applicable; PANSS, Positive and Negative Syndrome Scale; PET, positron emission tomography.
a
χ2 test.
b
Independent samples t test.
c
Receiving antipsychotic medication for 2 weeks or less.
d
Kruskal-Wallis test.